News
Latest News
The collaboration will support community change to address inequality and drive impact
More than 125 life science leaders and representatives from more than 65 companies joined the leading trade…
The relationship will support educational programs for all ages at the historic site
We are excited to announce NewYorkBIO’s new Incubator & Accelerator Membership tiers, created to empower…
In 2025, NewYorkBIO launched New York Bio Connect, a first-of-its-kind resource hub. Designed for…
The award celebrates innovation, economic impact, and leadership in New York City’s thriving life sciences…
New York’s leading life science advocacy association and economic development organizations develop resource…
StatNews 09/07/2026
Novo Nordisk has stopped two trials of a drug that aims to tame inflammation as a way to improve ...
09/04/2026
A closely watched cardiovascular drug from Novartis failed in a pivotal study, the company said ...
09/04/2026
After the failure of an experimental drug for Angelman syndrome, experts cautioned that there is ...
09/04/2026
The biggest barrier for a top schzophrenia treatment, Ionis' first approval for Alexander disease, ...
09/03/2026
Zanvastro is the first disease-modifying treatment for Alexander disease, a rare and fatal disorder.
09/03/2026
Ultragenyx drug fails pivotal Phase 3, FDA's success at regulating unproven stem cells, and other ...
09/03/2026
Biotech M&A activity is off the charts, yet the French drugmaker Abivax hasn't been picked up ...
09/03/2026
“These successes are surprising, worth discussing, and even celebrating a bit,” STAT Lab Dish ...
09/02/2026
Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit ...